Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug415 | Awake prone positioning Wiki | 1.00 |
| drug3748 | Standard oxygen therapy Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a pilot, multi-centre, open-label randomised controlled study to assess the early efficacy of intravenous (IV) administration of CYP-001 in adults admitted to an intensive care unit (ICU) with COVID-19.
Description: Assessment of respiratory dysfunction
Measure: Trend in trajectory of PaO2/FiO2 ratio (P/F ratio) between groups Time: 7 daysDescription: Assessment of safety
Measure: Incidence and severity of treatment-emergent adverse events Time: 28 daysDescription: Circulating biomarker of inflammation
Measure: Change in C-reactive protein (CRP) levels Time: 7 daysDescription: Not hospitalised, with resumption of normal activities = 1; Not hospitalised, but unable to resume normal activities = 2; Hospitalised, not requiring supplemental oxygen = 3; Hospitalised, requiring supplemental oxygen = 4; Hospitalised, requiring humidified nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both = 5; Hospitalised, requiring invasive mechanical ventilation, extracorporeal membrane oxygenation or both = 6; Death = 7
Measure: Proportional differences between groups on the Clinical Improvement Scale Time: 28 daysDescription: Assessment of respiratory dysfunction
Measure: Changes in P/F ratio Time: 28 daysDescription: Assessment of respiratory dysfunction
Measure: Changes in respiratory rate Time: 28 daysDescription: Assessment of respiratory dysfunction
Measure: Changes in oxygenation index Time: 28 daysDescription: Assessment of respiratory dysfunction
Measure: Changes in respiratory compliance (the change in lung volume per unit change in transmural pressure gradient) Time: 28 daysDescription: Assessment of respiratory dysfunction
Measure: Changes in positive end-expiratory pressure Time: 28 daysDescription: Number of days from the time of initiating unassisted breathing to D28, assuming survival for at least 48 hours after initiating unassisted breathing and continued unassisted breathing to D28
Measure: Ventilator-free days Time: 28 daysDescription: Quality of life assessment
Measure: Proportional differences between groups on the SF-36 Time: 28 daysDescription: Disability assessment
Measure: Proportional differences between groups on the mini mental state examination Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports